JP2024503637A - 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用 - Google Patents

線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用 Download PDF

Info

Publication number
JP2024503637A
JP2024503637A JP2023541264A JP2023541264A JP2024503637A JP 2024503637 A JP2024503637 A JP 2024503637A JP 2023541264 A JP2023541264 A JP 2023541264A JP 2023541264 A JP2023541264 A JP 2023541264A JP 2024503637 A JP2024503637 A JP 2024503637A
Authority
JP
Japan
Prior art keywords
group
cys
amino acid
pro
acid residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541264A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024503637A5 (enExample
Inventor
オステルカンプ，フランク
ズボロウスキー，ディルク
シュナイダー，エベラール
ハーセ，クリスチャン
パシュケ，マティアス
ヘーネ，アイリーン
ウンゲウィス，ヤン
スマーリング，クリスチャン
ライニキー，ウルリッチ
ブレーデンベック，アン
フォン・ハット，ジャン・レンナルト
ワフスナー・テシュナー，ジェシカ
Original Assignee
３ベー ファーマシューティカルズ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ３ベー ファーマシューティカルズ ゲーエムベーハー filed Critical ３ベー ファーマシューティカルズ ゲーエムベーハー
Publication of JP2024503637A publication Critical patent/JP2024503637A/ja
Publication of JP2024503637A5 publication Critical patent/JP2024503637A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8103—Exopeptidase (E.C. 3.4.11-19) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14001—Dipeptidyl-peptidase I (3.4.14.1), i.e. cathepsin-C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21026—Prolyl oligopeptidase (3.4.21.26), i.e. proline-specific endopeptidase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2023541264A 2021-01-07 2022-01-07 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用 Pending JP2024503637A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163134704P 2021-01-07 2021-01-07
US63/134,704 2021-01-07
PCT/EP2022/050280 WO2022148843A1 (en) 2021-01-07 2022-01-07 Compounds comprising a fibroblast activation protein ligand and use thereof

Publications (2)

Publication Number Publication Date
JP2024503637A true JP2024503637A (ja) 2024-01-26
JP2024503637A5 JP2024503637A5 (enExample) 2025-11-12

Family

ID=80050672

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541264A Pending JP2024503637A (ja) 2021-01-07 2022-01-07 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用

Country Status (11)

Country Link
US (1) US20230212549A1 (enExample)
EP (1) EP4274835A1 (enExample)
JP (1) JP2024503637A (enExample)
KR (1) KR20230129261A (enExample)
CN (1) CN116940585A (enExample)
AU (1) AU2022205523A1 (enExample)
CA (1) CA3206863A1 (enExample)
CL (5) CL2023001991A1 (enExample)
IL (1) IL303925A (enExample)
MX (1) MX2023007869A (enExample)
WO (1) WO2022148843A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220072092A1 (en) * 2016-06-24 2022-03-10 University Of Iowa Research Foundation Compositions and methods of treating melanoma
PL3997103T3 (pl) 2019-07-08 2025-03-24 3B Pharmaceuticals Gmbh Związki zawierające ligand białka aktywującego fibroblasty i ich zastosowanie
EP4475900A1 (en) 2022-02-09 2024-12-18 Novartis AG Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent
CN118754936A (zh) * 2023-03-27 2024-10-11 晶核生物医药科技(南京)有限公司 环状多肽类化合物及其应用
EP4692105A1 (en) * 2023-03-27 2026-02-11 Bivision Pharmaceuticals, Inc Cyclic polypeptide compound and use thereof
CN118754937A (zh) * 2023-03-27 2024-10-11 晶核生物医药科技(南京)有限公司 环状多肽类化合物及其应用
CN118930606A (zh) * 2023-05-11 2024-11-12 成都纽瑞特医疗科技股份有限公司 靶向成纤维细胞活化蛋白的多肽放射性核素配合物及其应用
AU2024304266A1 (en) * 2023-06-14 2025-12-04 Mariana Oncology Inc. Dll3 targeting peptides and constructs thereof
CR20260011A (es) * 2023-06-14 2026-05-15 Mariana Oncology Inc Péptidos dirigidos a dll3 y sus construcciones
JP2026521249A (ja) * 2023-06-14 2026-06-29 マリアナ オンコロジー インコーポレーテッド Ｄｌｌ３標的化ペプチド及びその構築物
TW202502800A (zh) * 2023-07-11 2025-01-16 大陸商江蘇恆瑞醫藥股份有限公司 一種成纖維細胞活化蛋白配體及其用途
WO2025082283A1 (zh) * 2023-10-16 2025-04-24 四川科伦博泰生物医药股份有限公司 环肽结构的配体化合物及其核素标记物、药物组合物及应用
WO2025117586A1 (en) * 2023-11-27 2025-06-05 Mariana Oncology Inc. Dll3 targeting peptides and constructs thereof
US20250186630A1 (en) * 2023-12-12 2025-06-12 Viewpoint Molecular Targeting, Inc. Fibroblast activation protein targeting peptides
AU2025214491A1 (en) 2024-02-01 2026-08-06 Novartis Ag Methods for treating cancer
TW202600606A (zh) * 2024-02-21 2026-01-01 美商雅博得樂醫療公司 抗體連接子結合物
WO2025179168A1 (en) * 2024-02-22 2025-08-28 Mariana Oncology Inc. Synthesis of dll3-binding peptides
CN118725026B (zh) * 2024-06-07 2026-05-01 中国科学院上海药物研究所 一类靶向肿瘤相关成纤维细胞激活蛋白的糖肽、放射性核素标记物及其应用
WO2026046340A1 (zh) * 2024-08-30 2026-03-05 江苏恒瑞医药股份有限公司 一种f-18标记反应前体分子的方法
WO2026056964A1 (zh) * 2024-09-14 2026-03-19 四川科伦博泰生物医药股份有限公司 环肽结构的配体化合物及其核素标记物、药物组合物及应用
WO2026149506A1 (zh) * 2025-01-10 2026-07-16 天津恒瑞医药有限公司 一种药物组合物及其制备方法
WO2026149529A1 (zh) * 2025-01-10 2026-07-16 天津恒瑞医药有限公司 一种成纤维细胞活化蛋白配体及其用途
WO2026163110A1 (en) 2025-01-30 2026-08-06 Novartis Ag Combinations with fap targeting compounds and conjugates thereof
CN121494877A (zh) * 2025-10-24 2026-02-10 复旦大学附属眼耳鼻喉科医院 一种硼原子标记的靶向成纤维细胞激活蛋白的化合物及其制备方法和应用
CN121045338B (zh) * 2025-11-05 2026-05-19 原子高科股份有限公司 一种靶向caix的环肽及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006042282A2 (en) * 2004-10-12 2006-04-20 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
JP2018515066A (ja) * 2015-03-17 2018-06-14 バイオンテック アーゲー がんの診断及び処置のための組成物及び方法
WO2019083990A2 (en) * 2017-10-23 2019-05-02 The Johns Hopkins University IMAGING AND RADIATION THERAPY AGENTS TARGETING α-FIBROBLAST ACTIVATION PROTEIN α (FAP-α)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
JP2001518290A (ja) 1997-09-29 2001-10-16 ポイント セラピューティクス， インコーポレイテッド インビトロでの造血細胞の刺激
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
CA2401252A1 (en) 2000-03-17 2001-09-20 Boehringer Ingelheim Pharma Kg Human and humanized fap-alpha-specific antibodies
CA2606785A1 (en) 2005-05-19 2006-11-23 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods
US8933201B2 (en) 2006-06-07 2015-01-13 The Board Of Regents Of The University Of Oklahoma Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use
CA2681351A1 (en) 2007-03-20 2008-09-25 Trustees Of Tufts College Inhibitors of fibroblast activation protein, and methods of use thereof
CN102203061A (zh) 2008-09-25 2011-09-28 分子制药洞察公司 选择性seprase抑制剂
WO2011040972A1 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Anti-fibroblast activation protein antibodies and methods and uses thereof
PE20171512A1 (es) 2010-08-13 2017-10-20 Roche Glycart Ag Anticuerpos anti-fap
WO2013107820A1 (en) 2012-01-17 2013-07-25 Universiteit Antwerpen Novel fap inhibitors
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
CR20180581A (es) 2016-06-10 2019-02-11 Bayer Pharma AG Complejos radio-farmacéuticos
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
EP3763726A1 (en) * 2019-07-08 2021-01-13 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006042282A2 (en) * 2004-10-12 2006-04-20 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
JP2018515066A (ja) * 2015-03-17 2018-06-14 バイオンテック アーゲー がんの診断及び処置のための組成物及び方法
WO2019083990A2 (en) * 2017-10-23 2019-05-02 The Johns Hopkins University IMAGING AND RADIATION THERAPY AGENTS TARGETING α-FIBROBLAST ACTIVATION PROTEIN α (FAP-α)

Also Published As

Publication number Publication date
US20230212549A1 (en) 2023-07-06
CL2024001596A1 (es) 2024-10-11
EP4274835A1 (en) 2023-11-15
IL303925A (en) 2023-08-01
CL2024001600A1 (es) 2024-10-11
CN116940585A (zh) 2023-10-24
AU2022205523A1 (en) 2023-07-13
CL2023001991A1 (es) 2023-12-15
CL2024001599A1 (es) 2024-10-11
WO2022148843A1 (en) 2022-07-14
MX2023007869A (es) 2023-09-22
CL2024001597A1 (es) 2024-10-11
KR20230129261A (ko) 2023-09-07
CA3206863A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
JP7801207B2 (ja) 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
JP7783396B2 (ja) 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
US20230212549A1 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
JP2024503635A (ja) 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
EP3763726A1 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
AU2022410422B2 (en) Carbonic anhydrase ix ligands
CN118591549A (zh) 碳酸酐酶ix配位体
EP4610269A1 (en) Urokinase plasminogen activator surface receptor (upar) ligands for diagnostic or therapeutic use
TW202334177A (zh) 包含纖維母細胞活化蛋白配體之化合物和彼之用途
WO2025088200A2 (en) Acid phosphatase 3 ligands for targeted delivery applications

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260611